MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-UK-05-0001594
Mepromax Life Sciences Private Limited - pharma in Wadhwan, Gujarat, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹82.29 Cr
▲ 2% YoY
Net profit · FY 2025
₹2.07 Cr
Net margin 2.5%
EBITDA · FY 2025
₹3.44 Cr
EBITDA margin 4.2%
Authorised capital
₹1 Cr
Registered with MCA
Paid-up capital
₹85 Lakh
Issued & subscribed
Open charges
₹6.37 Cr
Satisfied ₹12.3 Cr
Company age
21 yrs
Est. 2005
Employees · EPFO
70
Provident fund records
About Mepromax Life Sciences Private Limited
Data last updated:
Mepromax Life Sciences Private Limited is a private limited company based in Wadhwan, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 April 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24231GJ2005PTC045918. Its GSTIN is 05AAECM2429E1ZV (Uttarakhand). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹85 Lakh. It is led by directors including Prakash Navinchandra Shah (Whole-Time Director) and Bharatkumar Chabildas Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at GIDC Residential Plot No. H/78, Wadhwan, Gujarat, India – 363035.
As per the financials filed for FY 2025, the company reported a revenue of ₹82.29 Cr, a growth of 2% compared to the previous year. For the same year it recorded a net profit of ₹2.07 Cr (net margin 2.5%) and EBITDA of ₹3.44 Cr (EBITDA margin 4.2%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years and 1% over five years.
The company has about 70 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹6.37 Cr and satisfied charges of ₹12.3 Cr on record. Court records list 4 cases involving the company, including 1 filed by the company and 3 filed against it; 2 cases are pending. The company has 6 deals on record (5 secondary share transfers, 1 funding round), with disclosed funding of ₹99 Lakh; the latest was in March 2023. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Wexford Laboratories Private Limited with revenue of ₹83.63 Cr. The company has 11 MSME Form 1 returns on record between 2019 and 2023, listing 581 overdue payments to 73 micro and small suppliers.
Mepromax Life Sciences Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-UK-05-0001594). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mepro.in.
Company details
CIN U24231GJ2005PTC045918
Registration Number 045918
Incorporation Date 21 April 2005
ROC Ahmedabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-UK-05-0001594
Key People
Prakash Navinchandra Shah Whole-Time Director Bharatkumar Chabildas Shah Whole-Time Director Suresh Chhabildas Shah Whole-Time Director Recognitions & Rankings of Mepromax Life Sciences
Contact details
Mepromax Life Sciences Private Limited's registered office is in Wadhwan, Gujarat. Its website is mepro.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressGIDC Residential Plot No. H/78, Wadhwan, Gujarat, India – 363035
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Mepromax Life Sciences Private Limited, buy the company report.
Comprehensive company report
Mepromax Life Sciences Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Mepromax Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Mepromax Life Sciences Private Limited, buy the company report.
Financials of Mepromax Life Sciences Private Limited
FY 2025 filings availableMepromax Life Sciences Private Limited reported revenue of ₹82.29 Cr (up 2% YoY) for FY 2025.
Revenue · FY 2025
₹82.29 Cr ▲ 2%
Net profit · FY 2025
₹2.07 Cr margin 2.5%
EBITDA · FY 2025
₹3.44 Cr margin 4.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 2%
3 years · compounded
▲ 5%
5 years · compounded
▲ 1%
EBITDA CAGR growth
1 year
▲ 10%
3 years · compounded
▲ 28%
5 years · compounded
▲ 12%
Revenue has grown at a compounded annual rate (CAGR) of 1% over five years, including 2% growth in the latest year. EBITDA rose 10% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.44 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.07 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.2% | ||||
| Net Profit Margin | 2.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Mepromax Life Sciences Private Limited, buy the company report.
Board of directors of Mepromax Life Sciences Private Limited
Mepromax Life Sciences has 4 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prakash Navinchandra Shah Also directs: Mepro Pharmaceuticals Private Limited | Whole-Time Director | 15 Jun 2006 | 20 Years 4 Months | Current |
| Bharatkumar Chabildas Shah Also directs: Mepro Pharmaceuticals Private Limited, Sunshine Organics Pvt Ltd | Whole-Time Director | 15 Jun 2006 | 20 Years 4 Months | Current |
| Suresh Chhabildas Shah Also directs: Mepro Pharmaceuticals Private Limited | Whole-Time Director | 15 Jun 2006 | 20 Years 4 Months | Current |
| Rajesh Sumanlal Shah | Whole-Time Director | 15 Jun 2006 | 20 Years 4 Months | Current |
Peer comparison
Mepromax Life Sciences Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Wexford Laboratories Private Limited | ₹83.63 Cr (FY 2024) | 22.0% | Tumkur, Karnataka, India | |||
| Brooks Laboratories Limited | ₹83.44 Cr (FY 2025) | 4.0% | Nalagarh, Himachal Pradesh, India | |||
| J Duncan Healthcare Private Limited | ₹82.47 Cr (FY 2025) | -57.0% | Shahapur, Maharashtra, India | |||
| Maxheal Pharmaceuticals (India) Limited | ₹82.41 Cr (FY 2024) | 10.0% | Mumbai, Maharashtra, India | |||
| Mepromax Life Sciences Private Limitedthis company | ₹82.29 Cr (FY 2025) | ₹2.07 Cr | 2.5% | 2.0% | 70 | Wadhwan, Gujarat, India |
| Himalaya Meditek Private Limited | ₹82.23 Cr (FY 2024) | 3.0% | Hyderabad, Telangana, India | |||
| Beacon Diagnostics Pvt Ltd | ₹82.21 Cr (FY 2025) | -1.0% | Navsari, Gujarat, India | |||
| JFL Life Sciences Limited | ₹82.05 Cr (FY 2025) | 74.0% | Ahmedabad, Gujarat, India | |||
| Oscar Remedies Pvt Ltd | ₹82.04 Cr (FY 2025) | 15.0% | Haryana, India | |||
| Sun Life Sciences Private Limited | ₹81.57 Cr (FY 2024) | 17.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Mepromax Life Sciences Private Limited, buy the company report.
Auditor
Mepromax Life Sciences Private Limited is audited by DINESH KUMAR VADILAL SHAH for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DINESH KUMAR VADILAL SHAH | FY 2024 | 125102W |
Shareholding
The shareholding of Mepromax Life Sciences Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Mepromax Life Sciences Private Limited, buy the company report.
Charges & borrowings
Open charges
₹6.37 Cr
Satisfied charges
₹12.3 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 14 Sep 2007 | 10074912 | Others | ₹6.37 Cr | Open | |
| 19 Jan 2007 | 10060904 | Icici Bank Limited | ₹6.15 Cr | Satisfied | |
| 31 Jul 2006 | 10031789 | Icici Bank Limited | ₹6.15 Cr | Satisfied |
To see the full charge records of Mepromax Life Sciences Private Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Mepromax Life Sciences Private Limited has 6 deals on record (5 secondary share transfers, 1 funding round), with disclosed funding of ₹99 Lakh; the latest was in March 2023.
Total deals
6
Secondary share transfers
5
Funding round
1
Disclosed funding
₹99 Lakh
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 4 individuals |
| Mar 2022 | Secondary share transfer | Undisclosed | Seller: an individual |
| Mar 2013 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Skymax Laboratories Limited , an individual |
| Mar 2010 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Skymax Laboratories Limited |
| Jul 2006 | Funding round | ₹99 Lakh | Investors: 4 individuals |
To see the full deal history of Mepromax Life Sciences Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Mepromax Life Sciences Private Limited has 4 court cases on record: 1 filed by Mepromax Life Sciences, 3 filed against it. 2 cases are pending and 2 are disposed.
Total cases
4
Filed by the company
1
Filed against the company
3
Pending
2
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 3 | 1 |
| High courts | 1 | 0 | 1 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Civil suit | Filed against the company by Vanraj and Co. Private Limited | Disposed |
| High Court of Uttarakhand | Court case (WPMB) | Filed by the company against The Union of India | Pending |
| District court, Akola, Maharashtra | Civil suit | Filed against the company | Pending |
| District court, Akola, Maharashtra | Criminal miscellaneous application | Filed against the company by State of Maharashtra | Disposed |
To see the full case history of Mepromax Life Sciences Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Mepromax Life Sciences Private Limited has 11 MSME Form 1 returns on record between 2019 and 2023, listing 581 overdue payments to 73 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 73)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Avik Pharmaceutical Limited | |||
| an individual supplier | |||
| Multani Pharmaceuticals Limited | |||
| Vizitech Packaging |
To see the full MSME payment records of Mepromax Life Sciences Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Mepromax Life Sciences Private Limited has a workforce of 70 employees on its EPFO records as of Mar 29, 2025, across 1 active EPFO establishment.
Employee count
70
Active EPFO establishments
1
GST
Mepromax Life Sciences has 3 GST registrations: 2 active and 1 cancelled or inactive.
Total GSTINs
3
Active
2
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 05AAECM2429E1ZV | Uttarakhand | Active | 01 Jul 2017 |
| 27AAECM2429E1ZP | Maharashtra | Active | 26 Jul 2017 |
To see the full GST registrations and return filing status of Mepromax Life Sciences Private Limited, buy the company report.
Recent activity
Mepromax Life Sciences Private Limited has 11 board changes on record since 2006: 4 appointments and 7 cessations. The latest: Bharatkumar Chabildas Shah ceased to be Director on 20 Jan 2015.
AGM
Mepromax Life Sciences Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Mepromax Life Sciences Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Charges
A charge with Others of Rs. 6.37 Cr registered on 14 Sep 2007 with Charge ID 10074912 was modified on 21 Aug 2017.
Ceased
Bharatkumar Chabildas Shah ceased to be Director.
Ceased
Prakash Navinchandra Shah ceased to be Director.
Ceased
Rajesh Sumanlal Shah ceased to be Director.
Ceased
Suresh Chhabildas Shah ceased to be Director.
Ceased
Chirag Jamanbhai Dadhania ceased to be Whole-Time Director.
Ceased
Anilkumar Rasiklal Patel ceased to be Director.
Charges
A charge registered on 19 Jan 2007 via Charge ID 10060904 with Icici Bank Limited was fully satisfied on 21 Jun 2012.
Charges
A charge registered on 31 Jul 2006 via Charge ID 10031789 with Icici Bank Limited was fully satisfied on 21 Jun 2012.
Ceased
Uttamkumar Rasiklal Javia ceased to be Director.
8 earlier events are in the company report.
Frequently asked questions
Mepromax Life Sciences is an active private limited company based in Wadhwan, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 April 2005 (21+ years old) and is registered under CIN U24231GJ2005PTC045918.
Mepromax Life Sciences has 4 current directors:
- Prakash Navinchandra Shah - Whole-Time Director
- Bharatkumar Chabildas Shah - Whole-Time Director
- Suresh Chhabildas Shah - Whole-Time Director
- Rajesh Sumanlal Shah - Whole-Time Director
The latest financial statements of Mepromax Life Sciences on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Mepromax Life Sciences is 05AAECM2429E1ZV, registered in Uttarakhand. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 27AAECM2429E1ZP (Maharashtra).
The CIN (Corporate Identification Number) of Mepromax Life Sciences is U24231GJ2005PTC045918. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Mepromax Life Sciences has 4 court cases on record: 1 filed by the company and 3 filed against it. 2 are pending. Most are in the district courts.
Mepromax Life Sciences was incorporated on 21 April 2005, making it 21+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Mepromax Life Sciences has 6 deals on record (5 secondary share transfers, 1 funding round), with disclosed funding of ₹99 Lakh; the latest was in March 2023.
The peers of Mepromax Life Sciences by revenue are Wexford Laboratories Private Limited, Brooks Laboratories Limited, J Duncan Healthcare Private Limited, Maxheal Pharmaceuticals (India) Limited, Himalaya Meditek Private Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Bharatkumar Chabildas Shah ceased to be Director on 20 Jan 2015. Prakash Navinchandra Shah ceased to be Director on 20 Jan 2015. Rajesh Sumanlal Shah ceased to be Director on 20 Jan 2015. Mepromax Life Sciences has 11 board changes on record in total.
Yes, Mepromax Life Sciences is registered as a medium enterprise under Udyam registration (number: UDYAM-UK-05-0001594).
Mepromax Life Sciences has 11 MSME Form 1 returns on record between 2019 and 2023, listing 581 overdue payments to 73 micro and small suppliers. The latest return was filed on 20 Jun 2023.